EL
IRWD icon

Elberon LLC’s Ironwood Pharmaceuticals IRWD Stock Holding History

Elberon LLC’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-38,208
Closed -$350K – 12
2016
Q1 		$350K Buy
38,208
+13,134
+52% +$108K 0.64% 12
2015
Q4 		$243K Buy
+25,074
New +$242K 0.25% 22

Other funds holding IRWD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Elberon LLC's IRWD Position: Q2 2016 in Review

Elberon LLC sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2016, closing a stake of 38,208 shares — an estimated $350K sold.

Elberon LLC first reported a position in IRWD in Q4 2015 and held it in 2 quarters. The position peaked at $350K in Q1 2016. 145 funds tracked by Wall St. Rank hold IRWD as of Q2 2016.

  • Elberon LLC reported no remaining Ironwood Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Elberon LLC sold 38,208 Ironwood Pharmaceuticals shares in Q2 2016, an estimated $350K.
  • Elberon LLC first reported a position in Ironwood Pharmaceuticals in Q4 2015 and held it in 2 quarters.
  • Elberon LLC's Ironwood Pharmaceuticals position peaked at $350K in Q1 2016.
  • 145 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2016.

Based on Elberon LLC's 13F filing for Q2 2016, filed 15 Aug 2016.